CRISPR Therapeutics AG Current Ratio 2015-2021 | CRSP

Current and historical current ratio for CRISPR Therapeutics AG (CRSP) from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. CRISPR Therapeutics AG current ratio for the three months ending June 30, 2021 was 26.23.
CRISPR Therapeutics AG Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $2.62B $0.10B 26.23
2021-03-31 $1.83B $0.08B 22.05
2020-12-31 $1.72B $0.09B 18.21
2020-09-30 $1.39B $0.08B 16.53
2020-06-30 $0.97B $0.08B 12.96
2020-03-31 $0.93B $0.06B 16.87
2019-12-31 $0.99B $0.06B 17.29
2019-09-30 $0.66B $0.08B 8.32
2019-06-30 $0.44B $0.03B 13.96
2019-03-31 $0.45B $0.03B 15.84
2018-12-31 $0.47B $0.03B 16.81
2018-09-30 $0.50B $0.03B 15.39
2018-06-30 $0.33B $0.02B 17.89
2018-03-31 $0.35B $0.01B 24.42
2017-12-31 $0.25B $0.02B 17.12
2017-09-30 $0.26B $0.01B 21.34
2017-06-30 $0.28B $0.02B 17.79
2017-03-31 $0.30B $0.02B 17.53
2016-12-31 $0.32B $0.02B 14.56
2016-09-30 $0.23B $0.08B 2.97
2016-06-30 $0.25B $0.08B 3.09
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2014-12-31 $0.00B $0.00B 0.45
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.282B $0.001B
CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76